SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
SELLAS Life Sciences Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$10.49+0.51 (+5.11%)
Close on Oct 19, 2026
- Market cap
- $1.98B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
36.5%
74M of 202M shares
Institutional holders
192
63 new, 27 sold out
Net institutional buying
20M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $100.81K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 9,666,278 | 5.19% | 13G (passive) | Jun 30, 2026 |
| Amin Nathoo | 7,579,095 | 8.30% | 13G (passive) | Mar 31, 2025 |
| Tony Moore | 6,032,938 | 5.70% | 13G (passive) | Sep 30, 2025 |
| State Street Corporation | 12,996,558 | 7.00% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 12,136,331 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15,070,302 | 7.46% | $222.44M | +2,871,892 | 0.00% |
| State Street Corp | 12,996,558 | 6.44% | $191.83M | +4,600,202 | 0.01% |
| Vanguard Capital Management LLC | 8,226,105 | 4.07% | $121.42M | +700,176 | 0.00% |
| Geode Capital Management, LLC | 4,884,175 | 2.42% | $72.11M | +971,569 | 0.00% |
| Anson Funds Management LP | 4,500,000 | 2.23% | $66.42M | New | 3.94% |
| Jones Financial Companies Lllp | 2,304,561 | 1.14% | $28.55M | +629,484 | 0.01% |
| Vanguard Portfolio Management LLC | 2,161,099 | 1.07% | $31.90M | +698,293 | 0.00% |
| Susquehanna International Group, Llp | 2,050,597 | 1.02% | $30.27M | +1,653,541 | 0.00% |
| Northern Trust Corp | 1,619,928 | 0.80% | $23.91M | +343,944 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,335,166 | 0.66% | $19.71M | +132,327 | 0.00% |
| UBS Group AG | 1,252,757 | 0.62% | $18.49M | +507,338 | 0.00% |
| Morgan Stanley | 1,236,261 | 0.61% | $18.25M | −100,032 | 0.00% |
| Dagco, Inc. | 1,232,433 | 0.61% | $18.19M | +203,653 | 3.36% |
| Bnp Paribas Arbitrage, Snc | 1,072,022 | 0.53% | $15.82M | +1,025,006 | 0.01% |
| Bank Of America Corp /De/ | 787,949 | 0.39% | $11.63M | +146,266 | 0.00% |
| Wellington Management Group Llp | 597,309 | 0.30% | $8.82M | +252,531 | 0.00% |
| Goldman Sachs Group Inc | 585,035 | 0.29% | $8.64M | +29,122 | 0.00% |
| Charles Schwab Investment Management Inc | 565,008 | 0.28% | $8.34M | +84,404 | 0.00% |
| Bank of New York Mellon Corp | 530,025 | 0.26% | $7.82M | +51,659 | 0.00% |
| Jane Street Group, LLC | 508,429 | 0.25% | $7.50M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 192 | 74M | 36.5% | 63 / 78 | 26 / 27 | 25M | 5M |
| Q1 2026 | 160 | 54M | 26.7% | 67 / 53 | 18 / 16 | 31M | 4M |
| Q4 2025 | 112 | 35M | 17.6% | 28 / 49 | 19 / 9 | 11M | 9M |
| Q3 2025 | 94 | 33M | 16.3% | 21 / 31 | 18 / 5 | 9M | 3M |
| Q2 2025 | 79 | 27M | 13.3% | 40 / 22 | 7 / 6 | 20M | 8M |
| Q1 2025 | 45 | 14M | 7.1% | 18 / 18 | 3 / 4 | 8M | 0M |
| Q4 2024 | 31 | 6M | 3.1% | 6 / 10 | 5 / 8 | 1M | 0M |
| Q3 2024 | 33 | 5M | 2.7% | 9 / 10 | 5 / 4 | 2M | 0M |
| Q2 2024 | 30 | 4M | 2.0% | 9 / 12 | 2 / 9 | 1M | 5M |
| Q1 2024 | 30 | 8M | 3.8% | 7 / 8 | 6 / 8 | 5M | 1M |
| Q4 2023 | 31 | 4M | 1.7% | 8 / 13 | 3 / 5 | 2M | 1M |
| Q3 2023 | 28 | 3M | 1.4% | 5 / 9 | 6 / 2 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 8,654,720 | 4.29% | $127.74M | 1.19% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,906,922 | 2.93% | $87.19M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,928,335 | 2.44% | $72.74M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,134,837 | 1.06% | $31.51M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,063,963 | 1.02% | $20.66M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,742,114 | 0.86% | $25.71M | 0.17% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 883,026 | 0.44% | $8.22M | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 881,240 | 0.44% | $8.20M | 0.02% | May 31, 2026 |
| iShares Micro-Cap ETF | 632,184 | 0.31% | $9.33M | 0.61% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 604,612 | 0.30% | $5.63M | 0.31% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 458,889 | 0.23% | $4.59M | 0.06% | Jul 31, 2026 |
| Master Small Cap Index Series | 343,271 | 0.17% | $5.07M | 0.08% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 318,615 | 0.16% | $2.97M | 0.00% | May 31, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 293,250 | 0.15% | $2.94M | 0.59% | Jul 31, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 274,459 | 0.14% | $2.56M | 0.61% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Angelos M. Stergiou | President and CEO, Director | 1,976,604 | 0.98% | Jun 18, 2026 |
| John Thomas Burns | CFO | 609,254 | 0.30% | Jan 9, 2026 |
| Dragan Cicic | SVP, Chief Development Officer | 557,805 | 0.28% | Jan 9, 2026 |
| David A. Scheinberg | Director | 73,082 | 0.04% | Jan 9, 2026 |
| Nostrand Robert L. Van | Director | 82,900 | 0.04% | Jan 9, 2026 |
| Katherine Bach Kalin | Director | 154,400 | 0.08% | Jan 9, 2026 |
| John Varian | Director | 72,900 | 0.04% | Jan 9, 2026 |
| Jane Wasman | Director | 92,900 | 0.05% | Jan 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Angelos M. Stergiou President and CEO, Director | Jun 16, 2026 | Award | +1,065,000 | – | – | 1,759,183 |
| Dragan Cicic SVP, Chief Development Officer | Jan 7, 2026 | Award | +300,000 | – | – | 557,805 |
| David A. Scheinberg Director | Jan 7, 2026 | Award | +50,000 | – | – | 73,082 |
| John Thomas Burns CFO | Jan 7, 2026 | Award | +300,000 | – | – | 554,327 |
| John Varian Director | Jan 7, 2026 | Award | +50,000 | – | – | 72,900 |
| Nostrand Robert L. Van Director | Jan 7, 2026 | Award | +50,000 | – | – | 82,900 |
| Katherine Bach Kalin Director | Jan 7, 2026 | Award | +50,000 | – | – | 154,400 |
| Jane Wasman Director | Jan 7, 2026 | Award | +50,000 | – | – | 92,900 |
| John Thomas Burns CFO | Dec 3, 2025 | Other | −58,592 | $1.50 | $87.89K | 254,327 |
| Dragan Cicic SVP, Chief Development Officer | Dec 3, 2025 | Other | −63,800 | $1.50 | $95.70K | 257,805 |
| Angelos M. Stergiou President and CEO, Director | Dec 3, 2025 | Other | −187,066 | $1.50 | $280.60K | 686,966 |
| Katherine Bach Kalin Director | Nov 19, 2025 | Buy | +63,400 | $1.59 | $100.81K | 104,400 |
| Nostrand Robert L. Van Director | Jun 12, 2025 | Buy | +10,000 | $1.48 | $14.80K | 20,400 |
| Jane Wasman Director | May 30, 2025 | Buy | +20,000 | $1.69 | $33.80K | 30,400 |
| Katherine Bach Kalin Director | May 22, 2025 | Buy | +20,000 | $1.80 | $36.00K | 41,000 |
| John Varian Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| Jane Wasman Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| Dragan Cicic SVP, Chief Development Officer | Jan 10, 2025 | Award | +113,000 | – | – | 228,328 |
| Dragan Cicic SVP, Chief Development Officer | Jan 10, 2025 | Award | +81,300 | – | – | 309,628 |
| Angelos M. Stergiou President and CEO, Director | Jan 10, 2025 | Award | +257,000 | – | – | 615,132 |
| Angelos M. Stergiou President and CEO, Director | Jan 10, 2025 | Award | +243,900 | – | – | 859,032 |
| Katherine Bach Kalin Director | Jan 10, 2025 | Award | +12,500 | – | – | 21,000 |
| John Thomas Burns CFO | Jan 10, 2025 | Award | +81,300 | – | – | 299,062 |
| John Thomas Burns CFO | Jan 10, 2025 | Award | +113,000 | – | – | 217,762 |
| Nostrand Robert L. Van Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| David A. Scheinberg Director | Jan 10, 2025 | Award | +12,500 | – | – | 23,082 |
| John Thomas Burns CFO | Dec 4, 2024 | Other | −7,165 | $1.13 | $8.10K | 104,762 |
| Dragan Cicic SVP, Chief Development Officer | Dec 4, 2024 | Other | −8,256 | $1.13 | $9.33K | 115,328 |
| Angelos M. Stergiou President and CEO, Director | Dec 4, 2024 | Other | −28,289 | $1.13 | $31.97K | 358,132 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Jan 22, 2024 | Award | +35,000 | – | – | 117,225 |
| Angelos M. Stergiou President and CEO, Director | Jan 22, 2024 | Award | +159,000 | – | – | 376,421 |
| Robert Francomano Chief Commercial Officer | Jan 22, 2024 | Award | +20,000 | – | – | 40,918 |
| John Thomas Burns CFO | Jan 22, 2024 | Award | +47,000 | – | – | 101,927 |
| Nostrand Robert L. Van Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| John Varian Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| Jane Wasman Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| David A. Scheinberg Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,582 |
| Katherine Bach Kalin Director | Jan 22, 2024 | Award | +6,000 | – | – | 8,500 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Dec 6, 2023 | Other | −4,119 | $1.08 | $4.45K | 82,225 |
| John Thomas Burns CFO | Dec 6, 2023 | Other | −2,929 | $1.08 | $3.16K | 54,927 |
| Robert Francomano Chief Commercial Officer | Dec 6, 2023 | Other | −1,082 | $1.08 | $1.17K | 20,918 |
| Angelos M. Stergiou President and CEO, Director | Dec 6, 2023 | Other | −12,268 | $1.08 | $13.25K | 217,421 |
| Robert Francomano Chief Commercial Officer | Feb 2, 2023 | Award | +12,000 | – | – | 12,000 |
| David A. Scheinberg Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,582 |
| John Thomas Burns CFO | Feb 2, 2023 | Award | +20,000 | – | – | 49,347 |
| Angelos M. Stergiou President and CEO, Director | Feb 2, 2023 | Award | +58,000 | – | – | 219,689 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Feb 2, 2023 | Award | +20,000 | – | – | 76,344 |
| Jane Wasman Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Nostrand Robert L. Van Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Katherine Bach Kalin Director | Feb 2, 2023 | Award | +2,500 | – | – | 2,500 |
| John Varian Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Dec 5, 2022 | Sale | −2,153 | $2.59 | $5.58K | 56,344 |
| Angelos M. Stergiou President and CEO, Director | Dec 5, 2022 | Sale | −6,494 | $2.61 | $16.95K | 161,689 |
| John Thomas Burns Senior VP, Finance & CAO | Dec 5, 2022 | Sale | −1,159 | $2.59 | $3.00K | 29,347 |
| John Varian Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
| Nostrand Robert L. Van Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
| John Thomas Burns Senior VP, Finance & CAO | Jan 31, 2022 | Award | +9,600 | – | – | 27,244 |
| David A. Scheinberg Director | Jan 31, 2022 | Award | +1,900 | – | – | 2,082 |
| Angelos M. Stergiou President and CEO, Director | Jan 31, 2022 | Award | +44,000 | – | – | 165,167 |
| Jane Wasman Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.